VEGFA and Cognitive impairment: In a more recent longitudinal study, 30% of mRCC patients treated with anti-angiogenics were found to develop fatigue and cognitive disorders, while VEGF plasma levels measured at baseline, and 3 and 6 months from baseline, were associated with fatigue, but not with cognitive dysfunction (Joly et al., 2016).